Several treatments are available to help ease Alzheimer’s symptoms; however, none of these existing treatments are capable of slowing the progression of the disease and protecting the brain from further damage. Clinical researches are developing new treatments that may slow the progression of Alzheimer’s.
The SUVN-502 Study is to test whether an investigational medication, named SUVN-502, has an effect on the symptoms of Alzheimer’s disease when prescribed along with donepezil and memantine. SUVN-502 works on different brain pathways than standard treatments and will be administered to approximately 530 people with Alzheimer’s in the U.S. across 90 study centers.
Potential participants will be assessed by a study doctor to find out if they are eligible for the study, which is expected to last about 30 weeks. To be eligible for the SUVN-502 study, participants must meet the following criteria:
- Have a medical diagnosis of Alzheimer’s
- Have a friend or relative as a study partner who is willing to:
- Be in regular contact with the participant at least 12 hours per week across 3 to 5 days
- Provide feedback on the participant’s symptoms and well-being
- Assist the participant with taking all study medications
- Accompany the participant to all clinic visits
- If the study partner leaves the study, a replacement will need to be found in order for the participant to remain in the study
- Continue to take their existing Alzheimer’s treatment (which will be provided at no charge, with the exception of Namenda XR® and Namzarictm) during the entire course of the study, which will be:
- 10 mg donepezil once daily
- 10 mg memantine twice daily / 28 mg Namenda XR® once daily / or as part of combination therapy Namzarictm (28 mg memantine HCl/10 mg donepezil HCl qd)
Participants and their study partners will attend 5 clinic visits over the course of the 26-week treatment phase. During the clinic visits, the study team will check on the participant’s symptoms and overall health using standard medical tests, questionnaires and interviews.
Exiting the Study
Participants can leave the study at any time for any reason. A decision to leave the study, or a decision to not take part, will not affect the standard of care provided to the participant outside the study.